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The main aim of diabetic nephropathy monitoring is to identify molecular markers, that is, to ﬁnd changes occurring at
metabolome and proteome levels indicative of the disease’s development. The mass spectrometry methods available today have
been successfully applied to this ﬁeld. This paper provides a short description of the basic aspects of the mass spectrometric
methods used for diabetic nephropathy monitoring, reporting and discussing the results obtained using diﬀerent approaches.
1.Introduction
Diabetic nephropathy (DN) is one of the most important
chronic complications of diabetes and, because it is associ-
ated with an increased frequency of cardiovascular disease, it
is an important factor in the morbidity and mortality of the
latter[1].Worldwide,DNisalsoamajordeterminantofend-
stage renal disease (ESRD) in approximately 40% of patients
requiring kidney replacement [1]. The public health burden
of DN is consequently very high.
Although a number of factors have been associated with
the onset of DN—both genetic [2] and environmental (poor
glycemic control, hyperlipidemia, hypertension, smoking)
[3]—thepathogenesisofthisdiseasehasyettobethoroughly
clariﬁed.Ontheotherhand,acomprehensiveunderstanding
ofthisdisease’sphysiopathologyisfundamentaltothedesign
oftherapeutic approachescapableof preventing the develop-
ment of DN and of the consequent ESRD [4].
Diabetic nephropathy usually begins with the onset of
microalbuminuria,whichproceedstoproteinuria,increasing
creatininemia and azotemia, and ultimately develops into
ESRD. It is worth emphasizing that numerous, potentially
reversible functional changes take place in the kidney before
proteinuria sets in, including hyperﬁltration, hyperperfu-
sion, and an increase in the capillary permeability of the
macromolecules. Then come several morphological changes,
such as basement membrane thickening, mesangial expan-
sion,glomerulosclerosis,andtubulointerstizialﬁbrosis;these
changes are irreversible and can trigger the onset of ESRD
[5, 6]. Measuring urinary albumin excretion is the method
generally used to classify DN, and a stable increase in mi-
croalbuminuria is considered the ﬁrst sign of renal damage
[7, 8]. About 20–40% of type 2 diabetic patients progress
to macroalbuminuria [9], and 40–50% of patients with mi-
croalbuminuria also suﬀer from cardiovascular disease [10].
These data further underscore the importance of identifying
patients prone to developing DN and consequently ESRD as
early as possible. Although albuminuria is considered one of
the main predictors of DN, there is still some controversy
concerning its sensitivity and speciﬁcity for this purpose
[11, 12]. It would, therefore, be useful to identify additional
protein markers capable of predicting whether patients with
diabetes risk developing DN even many years before the ﬁrst
clinical signs appear, and whether they risk suﬀering from
ESRD; this would certainly reduce the burden and social cost
of DN.2 ISRN Endocrinology
2.MassSpectrometricMethodsUsedto
Study DiabeticNephropathy
The onset of DN is necessarily reﬂected in a diﬀerent urinary
protein proﬁle.Albuminuria (i.e.,the albuminlevel in urine)
is widely used as a diagnostic test for the onset of neph-
ropathy despite persistent doubts as to its eﬃcacy [11, 12].
Developments in new analytical methods focusing on the
humanproteomemay,however,providephysicianswithvery
powerful tools capable of obtaining information on the
pathological mechanism(s) behind DN and enabling the
eﬃcacy of speciﬁc therapies to be assessed.
Mass spectrometry (MS) [13, 14]a ﬀords an extremely
interesting instrumental approach to describing a patient’s
urinary proﬁle, and it has been used in various ways in
the last decade to map the urinary proteins with a view to
identifyingthespeciesindicativeoftheonsetofnephropathy.
Giventhethousandsofproteinsandpeptidestobefound
in urine, the method used to identify them must be highly
sensitive and speciﬁc. A preliminary method used with some
success is one- and two-dimensional electrophoresis but,
here again, MS is needed to establish the molecular weight
and structure of the various proteins separated by the elec-
trophoretic method.
Generally speaking, two MS approaches have been most
widely used to study the urinary proteome (Figure 1)[ 15].
In one (on the left in Figure 1), the protein mixture is ﬁrst
treated by electrophoresis (be it one- or two-dimensional)
to separate the various proteins contained in the mixture. It
wouldbemoreaccuratetodeﬁnethisstepasa“partial”sepa-
ration procedure because neither one- nor two-dimensional
electrophoresis have a resolution high enough to separate all
the diﬀerent proteins. What is generally seen is more than
one protein in a given band (using monodimensional elec-
trophoresis) or spot (in 2D conditions). The denaturing
conditions of SDS-PAGE must also be taken into account.
The best results can be obtained with capillary zone elec-
trophoresis (CZE) [15], but this approach is more expensive
than 1D or 2D electrophoresis because of the cost of the
instrumentation required and the lengthy analysis times.
It is diﬃcult to obtain intact proteins from 1D or 2D
electrophoresis gel, due mainly to the small quantities of
the analytes. The proteins contained in a band or spot
are usually digested enzymatically and the structures of
the resulting peptides are then identiﬁed using suitable
MS procedures. This identiﬁcation step can be conducted
using tandem mass spectrometry (MS/MS) of protonated
molecules of the analytes generated by electrospray ion-
ization (ESI) [13]. The quality of the results depends on
the mass spectrometric resolution [14]: in high-resolution
conditions, structures are assigned on the basis not only of
the collisionally induced decomposition products (MS/MS),
but also of their elemental composition, obtained from
accurate mass measurements. This approach thus provides
information on some of the protein’s substructures (pep-
tides), not the original protein, and this latter information
must be obtained by comparing the tryptic fragments with
protein databases to obtain a list of possible proteins with
experimentally-determined amino acid sequences, using
aparametertoassessthevalidityofthestructuralassignment
[15].
The two MS methods generally used rely on two diﬀer-
ent ionization techniques, electrospray (ESI), and matrix-
assisted laser desorption ionization (MALDI). The power
of these methods has been recognized by the scientiﬁc
community with the assignment of the 1999 Nobel Prize to
John Fenn and Koichi Tanaka, the scientists who developed
ESI and MALDI, respectively.
Electrospraying involves spraying the analyte solution
generated by a strong electrical ﬁeld. These conditions
prompt the formation of charged droplets of the solution,
and evaporation of the solvent leads to an increase in the
droplets’ surface charge density and to the formation of the
protonated analyte ions in the gaseous phase. In the case of
proteins, the presence of a large number of basic sites within
their structure leads to the formation of multiprotonated
ion clusters from which it is easy to calculate the molecular
weight of the analyte. The power of ESI is related to the
ease with which it can be interfaced on-line with chromato-
graphic (LC) or electrophoretic (CZE) methods, so as to
obtain ESI mass spectra for each component separated using
the LC or CZE methods.
MALDI is based on the interaction of a laser beam with
a solid-state sample consisting of a suitable matrix (usually
variously substituted organic aromatic acids) in which the
analyte is contained at very low levels (in the typical matrix,
the ratio of the analyte is in the order of 10000:1). The
pulsed laser beam causes ionization of the matrix and a
rapid phase change, with the formation of a dense cloud
comprising the neutral and ionized matrix and molecules of
the analyte. In this region, ion-molecule reactions can occur
with a high yield, leading to the formation of protonated
molecules of the analyte. MALDI MS gives rise to the
formation of singly protonated species, so it can be useful
for characterizing protein mixtures without any need for
chromatographic separations. In other words, from a simple
MALDI spectrum we can obtain a “protein proﬁle” that cor-
relates well with the proteins most abundant in the mixture.
The drawback of the MALDI method is its low “dynamic
range” (in the order of 100–1000), which means that MALDI
only allows for a linear response between quantity and signal
to be obtained within this range. There may also be ion
suppression phenomena, which can give rise to quantitative
data that are not always reliable. To give an example,
introducing hemoglobin makes the two signals related to
globins α and β detectable with a high intensity, but their
abundance ratio is not 1:1, as we might expect, but 0.8:1,
indicating that β globin is ionized in a higher yield [16].
To obtain more speciﬁc protein proﬁles, samples can be
depositedondiﬀerentsurfacespriortolaserirradiation. This
approach is usually called SELDI (surface-enhanced laser
desorption/ionization), anditinvolvesdepositing thesample
and matrix on a surface modiﬁed to have a speciﬁc chemical
functionality before proceeding with laser ionization. Sur-
faces commonly used in this context include weakly positive
ion exchange, hydrophobic surfaces (similar to those used
in C6–C12 reverse phase chromatography), metal-binding
surfaces, and strong anion exchangers. Surfaces can alsoISRN Endocrinology 3
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Figure 1: Proposed approaches for proteomic investigations using mass spectrometry.
be functionalized with antibodies, other proteins, or DNA.
Only the analytes with a good aﬃnity with a given treated
surface will remain ﬁxed on the surface, while all the other
compounds are removed by washing. Then SELDI can be
used to enrich the substances of interest.
As shown in the ﬂow chart in Figure 1, using chromato-
graphic (LC) or electrophoretic (1D or 2D gel electrophore-
sis, or CZE) leads to the separation of the components in a
complex biological substrate and, when connected on-line
with MS (operating in ESI conditions) or oﬀ-line with a
MALDI/MS source (using suitable robotic devices), these
methods enable us to establish at least the molecular weight
of the diﬀerent proteins/peptides.
We say “at least” because the protonated molecular spe-
cies can be used in collisional experiments: they are select-
ed and decomposed by making them collide with a target
gas. Their collision prompts an internal energy deposition,
which promotes their fragmentation and provides valid
information on the protein/peptide amino-acid sequence.
As described below, interesting results in the ﬁeld of uri-
nary proteins have been obtained with all these instrumental
approaches, but the most powerful is CZE/MS.
Capillary electrophoresis can be used to separate ion
species contained in a solution based on their charge status,
hydrodynamic radius, and functional form. In other words,
electrically charged analytes move in a conducting medium
due to the action of an electrical ﬁeld. Many diﬀerent detec-
tors can be used to identify the diﬀerent analytes emerging
from the capillary tube, and mass spectrometry (usually
operating in ESI conditions) is the most sensitive and
speciﬁc. By comparison with LC, in which the molecular
species are separated by means of their aﬃnity for the4 ISRN Endocrinology
stationary phase, CZE shows a remarkably better resolution,
capable of separating the single components contained in a
highly complex natural matrix.
The results obtained by the diﬀerent approaches brieﬂy
outlined above, in terms of characterizing urinary protein
proﬁles, are described in more detail in Sections 3–6.
3. Results Obtained by Surface-Enhanced Laser
Desorption/Ionization
SELDI/MS generally produces valid results for protein
proﬁling in complex natural matrices. It has been and still
is used to identify any changes in the urinary protein proﬁles
of patients with diabetes and other diseases.
Suitable surfaces are used to select and concentrate the
analytes of interest.
The weakness of the method lies in the quality of MALDI
spectra, which is not as good as the quality achievable using
more complex MALDI machines. Any structure assigned by
means of MS/MS experiments cannot be obtained by SELDI;
the only analytical information it provides is the molecular
weight of the diﬀerent proteins/peptides in the sample.
In one study, SELDI was used to develop a method for
predicting diabetic nephropathy [17]: urine samples from 31
type 2 diabetic patients were analyzed systematically over a
decade, correlating changes in their urinary protein proﬁles
with any onset of DN. The SELDI data were considered
as a ﬁngerprint of an individual’s physiological/pathological
status, and diﬀerences were observed from a morphological
standpoint, without considering the possible protein struc-
tures. This method, nonetheless, showed that urinary pro-
teomic proﬁling with SELDI can identify normoalbuminuric
subjects with type 2 diabetes who will subsequently develop
DN.
SELDI mass spectrometry (using SAX2 protein assays)
wasusedtocompareurinaryproteinproﬁlesinfourdiﬀerent
groups of subjects, that is, type 2 diabetics (DM; n = 45)
with no nephropathy or microalbuminuria (DM WNP),
patients with DM and macro- or microalbuminuria (DM-
NP; n = 38), patients with proteinuria due to nondiabetic
renal disease (n = 34), and healthy controls (n = 45).
Strongly discriminating proteins were identiﬁed and isolated
using anion exchange, reversed-phase fractionation, gel elec-
trophoresis, and MS. One protein detected at m/z 6188 was
released in great abundance in the urine of healthy controls
and nephropathic cases without diabetes, and in cases of
DM WNP, but not in DM-NP patients [18]. Other proteins
were detected at m/z 14766 (selectively excreted in the urine
of DM-NP patients) and m/z 11774 (signiﬁcantly excreted
by patients with proteinuria and DM-NP). These last two
proteins were structurally identiﬁed as β2-microglobulin and
UbA52 (a ubiquitin ribosomal fusion protein), respectively.
Both could be considered interesting diagnostic markers. In
the kidney, UbA52 occurs exclusively in the renal tubules
and its expression was found proportional to the individual’s
blood glucose concentrations. Its expression is also regulated
by oxidative and carbonyl stress, which are important factors
in the pathophysiology of DN and apoptosis. Quantifying
the ubiquitin degradation product detected at m/z 6188 (the
level of which declined from healthy to DM-NP patients)
could provide interesting information on the development
of DN.
4. Result Obtained by Liquid Chromatography
andMass Spectrometry
The combination of liquid chromatography and mass spec-
trometry (LC/MS) has been used mainly to analyze digested
urinary proteins separated by 1D and 2D gel electrophoresis.
In this frame, Rao et al. recently conducted an extensive
study, taking the proteomic approach, to identify possible
biomarkers of DN [19]. They used DIGE (Diﬀerential in
Gel Electrophoresis) followed by tryptic peptide analysis with
LC/MS/MS to identify seven proteins that were upregulated
and four that were downregulated with increasing albumin-
uria levels.
This was achieved on the basis of amino acid sequences
obtained by MS/MS experiments performed on the tryptic
digestion products, and the resulting data were used for a
Lynx Global Server search. De novo sequencing was done
with a PEAKS algorithm combined with the Open Sea align-
ment algorithm. It is worth emphasizing that this approach
led to the identiﬁcation of 62 speciﬁc proteins belonging
t os e v e r a lf u n c t i o n a lg r o u p s( e . g . ,c e l ld e v e l o p m e n t ,c e l l
organization, defensive response, metabolism, and signal
transduction).
The proteins downregulated in DN were identiﬁed as
transthyretin, apolipoprotein A–I, α1-microglobulin/biku-
nin precursor, and plasma retinol-binding protein.
Seven proteins were upregulated (>1.5-fold; P<0.05)
in cases of DN with macroalbuminuria by comparison with
diabetics without albuminuria. Normalized volumes of these
upregulated proteins also increased gradually across three
categories of diabetic patients with normal, micro- and ma-
croalbuminuria, indicating the proteins’ positive association
with the progression of DN. The α1B-glycoprotein rose the
most overall (with a 7.0-fold increase), followed by zinc-
α2-glycoprotein (5.9-fold), α2-HS-glycoprotein (4.7-fold),
vitamin D-binding protein (VDBP) (4.8-fold), calgranulin B
(3.9-fold), α1-antitrypsin (A1AT) (2.9-fold), and hemopexin
(2.4-fold).
Compared with healthy controls, VDBP exhibited the
greatest increase (11.1-fold) followed by zinc-α2-glycoprote-
in (6.0-fold), α2-HS-glycoprotein precursor (2.3-fold), and
A1AT (2.2-fold).
Identifying the metabolic changes in these proteins can
be seen as a good starting point for elucidating the mecha-
nisms behind the pathogenesis of DN.
More recently, Riaz et al. [20] completed an in-depth
study using a very powerful separation method, that is,
2D liquid chromatography with chromatofocusing in the
ﬁrst dimension and reversed-phase chromatography in the
second, followed by MS analysis. This method was ﬁrst used
toseparatetheurinaryproteinsandascertaintheirmolecular
weight by MALDI/MS. To obtain structural information,
the proteins were digested and the peptides obtained wereISRN Endocrinology 5
analyzed by LC/MS and LC/MS/MS. The resulting data were
then compared with the human subset in the Swiss-Prot
protein database, and the protein assignments based on
these data were compared with the molecular weights of the
proteins obtained by MALDI.
The Riaz et al. investigation proved very highly speciﬁc
thanks to the high-resolution chromatographic method
adopted, the analysis of the molecular weight of intact uri-
naryproteins,theidentiﬁcationoftheproteinsbasedonpro-
tein digestion, and the structural assignment of the digestion
peptides based on the search in the database.
The transthyretin, α1-microglobulin/bikunin precursor,
and haptoglobin precursor levels were 30.8%, 55.2%, and
81.45% lower in the diabetics than in the controls, while
the levels of albumin, zinc-α2-glycoprotein, retinol binding
protein 4, and E-cadherin were 486.5%, 29.23%, 100%, and
693% higher, respectively. Changes in the levels of these
protein biomarkers have been reported in other pathological
states and assessing their levels will be helpful in the early
diagnosis and prognosis of diabetes mellitus type 2. These
data were interpreted on the assumption that bikunin is an
important anti-inﬂammatory substance and a decline in its
levels in pathological conditions may inﬂuence anti-inﬂam-
matory response. Lower levels of urinary α1-microglobulin
indicate a proximal tubular dysfunction and could serve as
an adjunctive biomarker (in addition to albuminuria levels)
for the early detection of nephropathy in diabetic subjects.
AmongthediﬀerentLC/MSapproachesusedtostudythe
urinary proteome, we must also mention the study by Tyan
et al. [21], based on nano-LC/MS/MS after enzymatic diges-
tion. The instrumental setup enabled the identiﬁcation of
2,283 peptides, corresponding to 311 proteins. The method
was unfortunately developed on urine from healthy subjects,
but its high speciﬁcity and the small quantity of sample
needed for the analysis suggest that this method could be
extremely eﬀective for studying changes in urinary protein
proﬁles in disease.
5.ResultsObtainedbyCapillaryZone
Electrophoresis andMass Spectrometry
Meanwhile, an extensive investigation was conducted by
Mischak et al. [22], focusing mainly on assessing diabetes-
related renal damage in humans in terms of urinary protein
proﬁle. Using a highly-speciﬁc method based on CZE cou-
pled with ESI-MS, the authors identiﬁed a “normal” urinary
polypeptide pattern in 39 healthy subjects that clearly
diﬀered from the pattern seen in 112 patients with type 2
DM. This prompted the identiﬁcation of a speciﬁc “diabetic”
pattern of polypeptide excretion. This approach led to the
detection of peptides pointing to diabetic renal damage in
patients with high albuminuria levels.
T h es a m ei n s t r u m e n t a la p p r o a c h( C Z E / E S I / M S )w a s
used to identify urinary protein patterns in type 1 diabetic
adolescents with early diabetic nephropathy [23]. Among
more than 1,000 diﬀerent polypeptides (in the mass range
of 800-66,500Da), the method was able to reveal a speciﬁc
cluster of 54 polypeptides found only in the urine of diabetic
patients.
In another study, CZE/MS analysis was used to analyze
changes in urinary polypeptide patterns during treatment
with the angiotensin II receptor blocker (ARB) candesartan
[24]: the treatment was found to signiﬁcantly change 15
of the 113 polypeptides characteristic of macroalbuminuric
patients, suggesting that this analytical approach can be
useful for monitoring the eﬃcacy of pharmacological treat-
ments.
CZE coupled with ESI-MS was also used recently by
Rossing et al. [25] to elucidate the panorama of urinary
proteomics in diabetes and chronic kidney disease (CKD).
Studying 305 subjects identiﬁed a panel of 40 biomarkers
capable of distinguishing diabetic patients from healthy sub-
jects with a 89% sensitivity and 91% speciﬁcity. The
distinction between cases of DN and other CKDs reached
a sensitivity of 81% and a speciﬁcity of 91%. Many of the
biomarkers identiﬁed were fragments of collagen type 1 and
they were in clearly lower quantities in patients with diabetes
orDN.Theuromodulinfragment589–607wasalsodetected.
Both the classic proteomics approach and CZE-based
measurements are highly-speciﬁc methods, but they have
the drawback of being diﬃcult to use in clinical chemistry
l a b o r a t o r i e s .T h e yb o t ht a k et i m ea n dd e m a n de x p e r i e n c e d
personnel and expensive equipments. Alternative analytical
approaches would, therefore, certainly be of interest.
The power of CZE-MS in the discovery, validation, and
clinical application of biomarker was exhaustively reviewed
very recently by Mischak and Schanstra [26], who describe
the instrumental setup in detail and draw a thorough com-
parison between the CZE-MS and LC-MS approaches. The
authors report that the main advantages of CZE are its
robustness, short run times and rapid reconditioning, which
a r eh e l p f u lw h e nl a r g en u m b e r so fh e t e r o g e n e o u ss a m p l e s
containing interfering compounds are being analyzed. The
main disadvantage of CZE lies in its limited loading capacity,
which negatively reﬂects on the feasibility of performing
MS/MS experiments. CZE fractions can be collected and
spotted oﬀ-line onto a MALDI target plate, however. The
polypeptides of interest can be sequenced by means of
MALDI TOF/TOF experiments, though the authors empha-
size that this approach is often unsuccessful, probably due
mainly to its low sensitivity and insuﬃcient mass accuracy.
Considering the great complexity of the urinary protein
proﬁle, as described in detail by CZE/MS, the subsequent
data analysis and statistics are an important issue when it
comes to identifying potential markers of disease. In the
case of CZE/MS, the migration time does not change very
much and an internal standard can be used to calibrate the
migration time successfully. These processes then lead to
the assignment of unique, readily reproducible parameters
that identify each peptide mass and migration time; signal
amplitude can be considered a valid measure of relative
abundance. These results can be used for statistical analyses,
thenthedatasetscanbeusedtoconductcomparativestudies
by multivariate analysis.
A recent paper [27] conﬁrmed the strength of this
approach: a multicenter validation of urinary proteomic6 ISRN Endocrinology
biomarkers speciﬁc for DN was implemented blindly using
CZE-MS, and the resulting data were assessed using the
model previously developed for DN. Samples from 148
Caucasian type 2 diabetic patients exhibiting albuminuria
>300mg/dL (cases), recruited at three diﬀerent European
centers, were analyzed and compared with those of 82
diabetic patients matched for gender and diabetes duration
(controls). Sixty previously identiﬁed peptides diﬀered sig-
niﬁcantlybetweencontrolsandpatients.Allthedataprocess-
ing was based on the classiﬁcation previously developed and
validated by Rossing et al. [25]f o rd i ﬀerentiating between
type 1 diabetic patients with and without macroalbuminuria
after CZE/MS analysis, obtaining a 100% sensitivity and a
97% speciﬁcity.
It is worth noting that it was only in under 10% of
cases and controls that the CZE/MS classiﬁcation did not
match the clinical data, but further evaluation of the patients
revealed a progression to DN in some of the false positive,
originally classiﬁed as DN controls patients. This point is of
interest, indicating that the proposed method is eﬀective in
identifying the early stages of DN.
Given its high speciﬁcity and the consequently large
number of urinary peptides identiﬁed, the CZE/MS ap-
proach provides to a broad panorama of the urinary pro-
teome that can be used successfully in biochemical consider-
ations strictly relating to pathophysiology [28]. In particular,
many urinary collagen fragments have been identiﬁed and
their levels are signiﬁcantly altered in diabetes. Monitoring
these collagen fragments enables type 1 and type 2 diabetic
patients to be distinguished from one another: speciﬁc
collagen fragments are associated with diabetes, and with the
type of diabetes, pointing to changes in collagen turnover
and extracellular matrix as a hallmark of the molecular
pathophysiology of diabetes. The data obtained by CZE-MS
show that the abundance of collagen fragments (collagen
alpha-1 [I] and [III]) decreases in the passage from being
healthytoacquiringdiabetesandthisdropismoreevidentin
cases of type 2 diabetes with no evidence of chronic kidney
disease than in type 1. Type 2 diabetic patients also exhibited
lower levels of microalbuminuria and higher levels of GFR
than in type 1 DM patients.
These ﬁndings may indicate that the impaired collagen
degradation mechanisms diﬀer (or occur with diﬀerent
yields) in the two types of diabetes.
6.Results ObtainedbyMatrix-AssistedLaser
Desorption/Ionization Mass Spectrometry
MALDI is a very diﬀerent analytical method from those
described so far. Two diﬀerent approaches are generally
used to apply MALDI in the proteome ﬁeld. One is
based on analyzing the enzymatic digestion products of
previously separated proteins/peptides (usually by 2D gel
electrophoresis). This method quickly provides the ﬁnger-
print of the digestion products to use in library searches. If
a higher speciﬁcity is needed, MS/MS experiments can be
performed on the digestion products to obtain their amino
acid sequences.
The second approach is based on the MALDI analysis of
intact urinary extracts, without any sample pre treatment.
Alongsidetheuseofcutoﬀmembranestoexcludethehigher-
molecular-weight proteins (e.g., albumin), using diﬀerent
matrices can lead to quite a complete ﬁngerprint of the
urinary protein proﬁle.
In both cases, a comparison must be drawn between
healthy subjects and patients with diﬀerent degrees of DN
to identify possible markers of the disease and thereby clarify
the metabolic changes responsible for it.
As mentioned in Introduction, the MALDI method does
not need coupling with chromatographic or electrophoretic
systems. The protein/peptide mixtures are analyzed directly,
generating a “ﬁngerprint” of the mixtures. A weakness of the
method lies in its limited dynamic range, which—together
with possible suppression eﬀects—may produce only a
partial view. The method’s speed of analysis, very wide mass
range (up to 500,000Da), and sensitivity (at fentomol level),
nonetheless, make MALDI a powerful tool for proteomic
studies.
The investigation conducted by Jiang et al. [29] is a good
exampleoftheﬁrstapproach.Urinesamplesfromtype2dia-
betic patients with normal albuminuria (DM), microalbu-
minuria (DN1), or macroalbuminuria (DN2) were analyzed
by comparison with those from a control group. The ﬁrst
step of this study relied on ﬂuorescence-based diﬀerence gel
electrophoresis (DIGE) followed by MS to identify possible
novel biomarkers. A total of 12 diﬀerently expressed proteins
came to light, 8 of them signiﬁcantly upregulated and 4
signiﬁcantly downregulated in the DN groups versus the
control group. Then the researchers focused on a novel
protein, E-cadherin, because of the magnitude of its change
(it was found upregulated 1.3-fold, 5.2-fold, 8.5-fold in the
D, DN1 and DN2 groups versus controls). This protein was
further studied in the urine by western blot and in renal
biopsies using immunohistochemical methods. Its urinary
levels were also obtained by ELISA.
E-cadherin is a 120kDa transmembrane glycoprotein
that plays a critical part in calcium-dependent cell-to-cell
junctional adherence. It is mainly located in the tubular
epithelial cells, with a key role in maintaining their structural
integrity. Renal ischemia and apoptosis could cause E-
cadherin degradation and cleavage via proteolytic enzyme
activation, leading to an increase in its levels in the urine.
Immunohistochemical data show a corresponding decrease
in E-cadherin expression.
The lower expression of E-cadherin in the kidney may,
therefore, correlate with the increased urinary levels of E-
cadherin seen in DN patients, but further studies are needed
to better clarify the role of this marker in the pathogenesis of
DN.
MALDI/MS was used by Kumar et al. [30]t oi n v e s t i g a t e
the proteomics of renal diseases. The approach taken in this
case was based on analyzing urine samples from patients
with diﬀerent renal conditions (end-stage renal disease,
nephropathic syndrome, and microalbuminuria) using 2D
electrophoresis, in gel proteolytic digestion, and MALDI
analysis of the digestion products. Patients with kidney
failure had more low-molecular-weight proteins, while thoseISRN Endocrinology 7
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Figure 2: MALDI mass spectra of urine samples from: (a) control subject, (b) diabetic patient, (c) nephropathic patient, and (d) diabetic-
nephropathic patient [31].
with nephrotic syndrome had a greater abundance of high-
molecular-weight proteins.
For patients with microalbuminuria, the proteins con-
sidered the most representative were Zn-α-2-glycoprotein,
alpha-1-microglobulin, and α-1-acid glycoprotein, α-1-acid
glycoprotein 2.
On the whole, the protein proﬁles obtained in diﬀerent
clinicalconditionswerequitediﬀerent,pointingtoapossible
diagnostic use of this method.
Unliketheapproachesdescribedbefore,MALDIhasbeen
used for the direct ﬁngerprinting of urinary proteins. The
results of a preliminary study [31] on urine samples from
type 2 diabetic patients, patients with renal disease, type
2 diabetic patients with renal disease, and healthy controls
showedthattheMALDIspectraofthelow-molecular-weight
fraction of the peptides in urine samples varied considerably
within each group, mainly as concerned their relative
abundance. This variability would suggest that the method is
unsuitableforcharacterizinggroups in diﬀerentpathological
states. Some diﬀerences became clearly apparent, however,
on comparing the spectra belonging to the diﬀerent groups
(see Figure 2, e.g.). It was immediately obvious that the
spectra from diabetic patients and healthy subjects were
quite similar: in both cases, the most abundant peak was
at m/z 1912, while other, less abundant peaks were seen
in both cases at m/z 1219 and 2049 (this last species was
underexpressed in samples from diabetic patients). The
peaks characteristic of the samples from healthy subjects and
diabetics were much lower in the case of nephropathic and
diabetic-nephropathic patients (whose most abundant peak
was at m/z 1219), whereas the ion at m/z 1912 was strongly
suppressed in these nephropathic patients.8 ISRN Endocrinology
The MS/MS spectrum of the ion at m/z 2049, obtained
by means of TOF-TOF experiments, was identical for all the
samples examined and the search using the Protein-Pilot
v.2.1 software in the Uniprot Database indicated that its
sequence is NGDDGEAGKPGRHypGERGPHypGP, corre-
sponding to the precursor of the collagen α-1 (I) chain [32].
Using the same approach, the ion at m/z 1912 was found to
have the sequence SGSVIDQSRVLNLGPITR and to coincide
with the uromodulin precursor. Finally, the ion at m/z 1219
was found to coincide with the IGPHypGPHypGLMGPP
sequence of the precursor of the collagen α-5 (IV) chain.
The histograms of the abundanceof the ions atm/z 1219,
1912, and 2049 in urine samples from the subjects under
study are shown in Figure 3.
The underexpression of the uromodulin fragment seen
in nephropathic patients with advanced renal disease and
in diabetic patients with advanced nephropathy might relate
to an alteration of the apical cell membrane of the thick
ascending limb (TAL) epithelial cells, while the collagen
fragments might be explained by an alteration of the renal
basal glomerular membrane.
Further investigations on a larger population conﬁrmed
these ﬁndings [33]. The results obtained underwent statis-
tical analysis, and the P values for the diﬀerences observed
indicate that they are statistically signiﬁcant when compar-
ison are drawn between all patients and healthy controls,
between diabetics with normal or microalbuminuria and
nephropathiccaseswithadvancedrenaldisease,andbetween
diabetics with normal or microalbuminuria and diabetics
with advanced nephropathy. The scatter plot shows the
strict inverse relationship between the abundance of ions at
m/z 1912 and 1219, with the correlation coeﬃcient being
particularly high (r = 0.921, P<0.001). The relationship
between the true positive rate (sensitivity) and the false
positive rate (1-speciﬁcity) for every possible cut-oﬀ in the
abundance of the ion species considered was investigated
using the receiver-operating characteristic (ROC) curve. The
data obtained indicate that a clear distinction can easily be
drawn between nephropathic patients with advanced renal
disease or diabetics with advanced nephropathy and healthy
controls using this approach (Figure 4).
7.FutureTrendstoBe Expected
The development of new analytical methods based on mass
spectrometry has been generating interesting and valid
results on the changes induced by diabetes in an individual’s
urinary protein proﬁle.
Two diﬀerent approaches have been taken, both based
on a ﬁrst separation step followed by MS analysis; these
two steps can be conducted on-line (as in the case of LC
or CZE/MS) or oﬀ-line (as in the case of 1D and 2D elec-
trophoresis). The protein is then generally characterized by
enzymatic digestion of the separated species and MS is used
to ascertain the molecular weight of the digestion products.
When analyzed with the aid of protein data banks, the
results enable the protein responsible for the production
of the digestion products to be identiﬁed. In the case of
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Figure 3: Histograms of the abundance of ions at m/z 1219, 1912,
and 2049 found in urine samples of the subjects under study. Data
are expressed as mean ± SEM [31].
CZE/MS, the enzymatic digestion phase is unnecessary and
the intact proteins are characterized on the strength of
their migration time and molecular weight. Finally, urinary
proteinmapscanbeobtainedbyMALDIwithoutpretreating
the sample.
To give an overview of the high number of data
obtained by the MS approaches, the diabetes urinary protein
biomarkers identiﬁed by the investigations above described
are reported in Table 1.
In this table, the peptide/proteins are listed for increasing
m/z values. For each of them, the name, the biological
processes which are involved, the type of disease, the regula-
tion together with the analytical method employed for their
detection, and the related reference are given.
In a further, wider table (available as supplementary
material available at doi:10.5402/2012/768159) all the pub-
lished data for both attributed and unattributed proteins, are
listed.
All these approaches have given us a clear idea of
the changes occurring in the urinary protein proﬁle due
to the development of diabetes. Some markers obtained
in this way have already been validated and these new
analyticalapproachescanbeexpectedtobeappliedatclinical
laboratory level in the near future, giving physicians new
diagnostictoolsforinvestigatingtheclinicalstatusofdiabetic
subjects and consequently developing suitable therapeutic
approaches.
Itisworthemphasizingthatsuchnewmassspectrometry
approaches are constantly evolving with the introduction of
instrumentation assuring an ultra-high speciﬁcity and sensi-
tivity. But for the time being, these instrumental approaches
demand highly experienced scientists and plenty of funds
for purchasing the necessary equipment—two aspects that
currently make these systems unsuitable for routine clinical
chemistry measurements.ISRN Endocrinology 9
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Figure 4: MALDI-TOF analysis of urinary-digested 2D electrophoretic protein spots from nephrotic syndrome patients (protein spots were
visualized by Coomassie staining and labelled NS1 to NS8). (a) Protein spots, corresponding to NS4, were subjected to in-gel digestion with
trypsin. On the left panel, tryptic peptide masses were obtained by MALDI-TOF analysis; on the right panel, comparison of experimentally
determined peptide masses of NS4 with theoretical peptide masses of α-1-antitrypsin. (b) MALDI-TOF proﬁles of tryptic peptides from
protein spots corresponding to NS5 (Left panel) were obtained by MALDI-TOF analysis: comparison of experimentally determined peptide
masses of RF2 with theoretical peptide masses of Zn-α-2-glycoprotein (Right panel). (c) MALDI-TOF proﬁles of tryptic peptides from
protein spots corresponding to NS8 (Left panel) were obtained by MALDI-TOF analysis: comparison of experimentally determined peptide
masses of NS8 with theoretical peptide masses of α-1-acid glycoprotein 2 (Right panel). Background peaks are marked with ‘∗’i nt h e
MALDI-TOF spectra [30].10 ISRN Endocrinology
Table 1: Diabetes urinary protein biomarkers. aAccession number in National Center for Biotechnology Information databases. DM:
Diabetic patients; DN: Diabetic nephropathy; DM-NP: Diabetic patients with macro- or microalbuminuria.
45.861 Haptoglobin
precursor P00738 Metabolism Type 2
DM-NP Downregulated DIGE followed
MALD1-TOF-MS [29]
46,707 α1-antitrypsin P01009 Defense
response
Type 2
DM-NP Upregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
51,643 α1-microglobulin/
bikunin precursor P02790 Transport Type 2
DM-NP Downregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
51,643 Hemopexin P02790 Defense
response
Type 2
DM-NP Upregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
52,964 Vitamin D-binding
protein P02774 Transport Type 2
DM-NP Upregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
54,239 α1B- Glycoprotein P04217 Function not
assigned
Type 2
DM-NP Upregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
71,317 Albumin P02768 Transport Type 2 DM Upregulated
Two-Dimensional
Liquid
Chromatography
followed by
MALDI
[20]
71,317 Serum albumin
precursor P02768 Transport Type 2
DM-NP Upregulated DIGE followed
MALDI-TOF-MS [29]
72,451 Uromodulin
precursor P07911 Defense
responsc
Type 2
DM-NP Downregulated DIGE followed
MALDI-TOF-MS [29]
72,984 Kininogen precursor P01042 Defense
response
Type 2
OM-NP Upregulated DIGE followed
MALDI-TOF-MS [29]
97.853 Epithelial-cadherin P12830 Cell adhesion Type 2 DM Upregulated
Two-Dimensional
Liquid
Chromatography
followed by
MALDI
[20]
97,853 Epithelial-cadherin P12830 Cell adhesion Type 2
DM-NP Upregulated DIGE followed
MALDI-TOF-MS [29]
2,049 Collagen α-1 (I)
chain precursor P02452 Structural
Component
Type 2
DM-NP and
NP
Upregulated MALDl/TOF/
TOF [31]
2,063 Collagen alpha-1
(III) chain P02461 Structural
Component Type 2 DM
Downregulated
with respect to
type i dm
CZE-MS [28]
2,192 Collagen α-1(I)
chain P02452 Structural
Component
Type 2
DM-NP Downregulated
CZE coupled
with ES1 mass
spectrometry
[25]
2,192 Collagen alpha-1(I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1dm
CZE-MS [28]
2,339 Collagen alpha-1(I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
2,377 Collagen α-1(I)
chain [227 to 250] P02452 Structural
Component
Type 2
DM-NP Downregulated
CZE coupled
with ESI mass
spectrometry
[25]
2,430 Collagen alpha-1(I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]ISRN Endocrinology 11
Table 1: Continued.
2,487 Collagen alpha-1(I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1dm
CZE-MS [28]
2,687 Collagen alpha-1(I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
3,092 Collagen alpha-1(I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
3,617 Collagen alpha-2(I)
chain P08123 Structural
Component Type 2 DM
Downregulated
with respect to
type i dm
CZE-MS [28]
3,802 Collagen alpha-2(I)
chain P08123 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
11,773 Ig Kappa Chain C
region P01834 Defense
response
Type 2
DM-NP Upregulated DIGE followed
MALDI-TOF-MS [29]
11,774 β2-microglobulin P61769 Defense
response
Type 2
DM-NP with
Proteinuria
Upregulated
anion exchange,
reversed-phase
fractionation, gel
electrophoresis
and SELDI-TOF
MS
[18]
13,234 Calgranulin B P06702 Defense
response
Type 2
DM-NP Upregulated
Using DIGE
followed
LC/MS/MS
peptide analysis
[19]
2,049 Collagen α-1 (I)
chain precursor P02452 Structural
Component
Type 2
DM-NP and
NP
Upregulated MALD/TOF/TOF [31]
2,063 Collagen alpha-1
(III) chain P02461 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
2,192 Collagen α-1(I)
chain P02452 Structural
Component
Type 2
DM-NP Downregulated
CZE coupled
with ESI mass
spectrometry
[25]
2,192 Collagen alpha-1 (I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
2,339 Collagen alpha-1 (I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
2,377 Collagen α-1 (I)
chain [227 to 250] P02452 Structural
Conioonent
Type 2
DM-NP Downregulated
CZE coupled
with ESI mass
spectrometry
[25]
2,430 Collagen alpha-1 (I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
2,487 Collagen alpha-1 (I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
2,687 Collagen alpha-1 (I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
3,092 Collagen alpha-1 (I)
chain P02452 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]12 ISRN Endocrinology
Table 1: Continued.
3,617 Collagen alpha-2(I)
chain P08123 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
3,802 Collagen alpha-2(l)
chain P08123 Structural
Component Type 2 DM
Downregulated
with respect to
type 1 dm
CZE-MS [28]
11,773 Ig Kappa Chain C
region P01834 Defense
response
Type 2
DM-NP Upregulated DIGE followed
MALDI-TOF-MS [29]
11,774 β2-microglobulin P61769 Defense
response
Type 2 DM-
NP with
Proteinuria
Upregulated
anion exchange,
reversed-phase
fractionation, gel
electrophoresis
and SELDI-TOF
MS
[18]
13,234 Calgranulin B P06702 Defense
response
Type 2
DM-NP Upregulated
Using DIGE
followed
LC/MS/MS
peptide analysis
[19]
45,861 Haptoglobin
precursor P00738 Metabolism Type 2
DM-NP Downregulated DIGE followed
MALDI-TOF-MS [29]
46,707 α1-antitrypsin P01009 Defense
response
Type 2
DM-NP Upregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
51,643 α1-microglobulin/
bikunin precursor P02790 Transport Type 2
DM-NP Downregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
51,643 Hemopexin P02790 Defense
response
Type 2
DM-NP Upregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
52,964 Vitamin D-binding
protein P02774 Transport Type 2
DM-NP Upregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
54,239 α1B-Glycoprotein P04217 Function not
assigned
Type 2
DM-NP Upregulated
DIGE followed
LC/MS/MS
peptide analysis
[19]
71,317 Albumin P02768 Transport Type 2 DM Upregulated
Two-Dimensional
Liquid
Chromatography
followed by
MALDI
[20]
71,317 Serum albumin
precursor P02768 Transport Type 2
DM-NP Upregulated DIGE followed
MALDI-TOF-MS [29]
72,451 Uromodulin
precursor P07911 Defense
response
Type 2
DM-NP Downregulated DIGE followed
MALDI-TOF-MS [29]
72,984 Kininogen precursor P01042 Defense
response
Type 2
DM-NP Upregulated DIGE followed
MALDI-TOF-MS [29]
97,853 Epithelial-cadherin P12830 Cell adhesion Type 2 DM Upregulated
Two-Dimensional
Liquid
Chromatography
followed by
MALDI
[20]
97,853 Epithelial-cadherin P12830 Cell adhesion Type 2
DM-NP Upregulated DIGE followed
MALDI-TOF-MS [29]ISRN Endocrinology 13
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